{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:57:11Z","timestamp":1794650231205,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>QT interval prolongation is a growing concern worldwide, posing psychiatric patients to life-threatening fatal arrhythmias i.e., torsade de pointes. This study aimed to identify the prevalence of QT interval prolongation, its associated risk factors and prescribing patterns of QT prolonging drugs among psychiatric patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>A prospective observational study was conducted that included psychiatric patients from a tertiary care hospital and a psychiatry clinic in Peshawar, Khyber Pakhtunkhwa, Pakistan. Electrocardiogram was recorded of those patients who were using psychotropic medications for \u22657\u2009days, aged 18\u2009years or more, and of either gender, male or female. The Fredericia correction formula was used for measuring QTc values (corrected QT). Chi-square test was applied to estimate differences between patients with or without prolonged QTc interval whereas, logistic regression analysis was performed to identify various predictors of QT interval prolongation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Out of 405 patients, the QTc interval was prolonged in 23 (5.7%) patients including 1 (0.2%) patient with highly abnormal prolonged QTc interval (&gt;\u2009500\u2009ms). QT drugs (91.6%), female sex (38.7%) and hypertension (10.6%) were the most common QT prolonging risk factors. Prolonged QTc interval was significantly higher among male patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.007).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In the present study, QT interval prolongation was observed in a considerable number of psychiatric patients. While, the high prevalence of QT prolonging risk factors among these patients warrants the increased risk of fatal arrhythmias. Therefore, risk assessment and electrocardiographic monitoring, and prescription of safer alternatives are highly recommended.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12888-020-02687-w","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:34:16Z","timestamp":1591194856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-5316","authenticated-orcid":false,"given":"Zahid","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-3399","authenticated-orcid":false,"given":"Mohammad","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Nazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahadullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"issue":"1","key":"2687_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40264-017-0584-4","volume":"41","author":"LM Hondeghem","year":"2018","unstructured":"Hondeghem LM, Drug-Induced QT. Prolongation and Torsades de pointes: an all-exclusive relationship or time for an amicable separation? Drug Saf. 2018;41(1):11\u20137. https:\/\/doi.org\/10.1007\/s40264-017-0584-4.","journal-title":"Drug Saf"},{"key":"2687_CR2","doi-asserted-by":"publisher","first-page":"212178","DOI":"10.1100\/2012\/212178","volume":"2012","author":"EM Kallergis","year":"2012","unstructured":"Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Sci World J. 2012;2012:212178. https:\/\/doi.org\/10.1100\/2012\/212178.","journal-title":"Sci World J"},{"issue":"11","key":"2687_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40261-015-0328-0","volume":"35","author":"TA Bhuiyan","year":"2015","unstructured":"Bhuiyan TA, Graff C, Kanters JK, Nielsen J, Melgaard J, Matz J, et al. The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs. Clin Drug Investig. 2015;35(11):717\u201324. https:\/\/doi.org\/10.1007\/s40261-015-0328-0.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"2687_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s11096-014-9953-6","volume":"36","author":"E Vandael","year":"2014","unstructured":"Vandael E, Marynissen T, Reyntens J, Spriet I, Vandenberghe J, Willems R, et al. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium. Int J Clin Pharm. 2014;36(4):757\u201365. https:\/\/doi.org\/10.1007\/s11096-014-9953-6.","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"2687_CR5","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1172\/JCI25539","volume":"115","author":"DM Roden","year":"2005","unstructured":"Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115(8):2025\u201332. https:\/\/doi.org\/10.1172\/JCI25539.","journal-title":"J Clin Invest"},{"issue":"1","key":"2687_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","volume":"70","author":"C van Noord","year":"2010","unstructured":"van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70(1):16\u201323. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03660.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2687_CR7","volume-title":"CredibleMeds Database","author":"RL Woosley","year":"2018","unstructured":"Woosley R.L., Heise C.W., Gallo T., Tate J., Woosley D., K.A. Romero. CredibleMeds Database. 2018. https:\/\/www.crediblemeds.org\/. Accessed 25 Sept 2018."},{"issue":"2","key":"2687_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00228-017-2381-5","volume":"74","author":"CPM Heemskerk","year":"2018","unstructured":"Heemskerk CPM, Pereboom M, van Stralen K, Berger FA, van den Bemt P, Kuijper AFM, et al. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018;74(2):183\u201391. https:\/\/doi.org\/10.1007\/s00228-017-2381-5.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2687_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1017\/S2045796015000906","volume":"25","author":"M Nose","year":"2016","unstructured":"Nose M, Bighelli I, Castellazzi M, Martinotti G, Carra G, Lucii C, et al. Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiol Psychiatr Sci. 2016;25(6):532\u201340. https:\/\/doi.org\/10.1017\/S2045796015000906.","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"11","key":"2687_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2146\/ajhp070279","volume":"65","author":"WR Zemrak","year":"2008","unstructured":"Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65(11):1029\u201338. https:\/\/doi.org\/10.2146\/ajhp070279.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"2687_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","volume":"67","author":"R Mojtabai","year":"2010","unstructured":"Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26\u201336. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2009.175.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"2687_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1017\/S1461145713000837","volume":"17","author":"HJ Moller","year":"2014","unstructured":"Moller HJ, Seemuller F, Schennach-Wolff R, Stubner S, Ruther E, Grohmann R. History, background, concepts and current use of comedication and polypharmacy in psychiatry. Int J Neuropsychopharmacol. 2014;17(7):983\u201396. https:\/\/doi.org\/10.1017\/S1461145713000837.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"2687_CR13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s11096-017-0532-5","volume":"39","author":"Q Khan","year":"2017","unstructured":"Khan Q, Ismail M, Haider I, Khan F. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study. Int J Clin Pharm. 2017;39(6):1256\u201364. https:\/\/doi.org\/10.1007\/s11096-017-0532-5.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"2687_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0973-1229.104497","volume":"11","author":"S Kukreja","year":"2013","unstructured":"Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82\u201399. https:\/\/doi.org\/10.4103\/0973-1229.104497.","journal-title":"Mens Sana Monogr"},{"issue":"10","key":"2687_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jaac.2010.07.007","volume":"49","author":"JS Comer","year":"2010","unstructured":"Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1001\u201310. https:\/\/doi.org\/10.1016\/j.jaac.2010.07.007.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"2687_CR16","first-page":"35","volume":"13","author":"SH Preskorn","year":"2006","unstructured":"Preskorn SH, Flockhart D. Blog archives 2006 guide to psychiatric Drug interactions. Primary Psychiatry. 2006;13(4):35\u201364.","journal-title":"Primary Psychiatry"},{"issue":"7","key":"2687_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1017\/S1461145713000837","volume":"17","author":"H-J M\u00f6ller","year":"2014","unstructured":"M\u00f6ller H-J, Seem\u00fcller F, Schennach-Wolff R, St\u00fcbner S, R\u00fcther E, Grohmann R. History, background, concepts and current use of comedication and polypharmacy in psychiatry. Int J Neuropsychopharmacol. 2014;17(7):983\u201396.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2687_CR18","doi-asserted-by":"crossref","unstructured":"Ghaemi SN, editor. Polypharmacy in psychiatry. Marcel Dekker, Inc., New York; 2002:101\u201332.","DOI":"10.1201\/b15278-5"},{"issue":"2","key":"2687_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/01.pra.0000265766.25495.3b","volume":"13","author":"SH PRESKORN","year":"2007","unstructured":"PRESKORN SH, LACEY RL. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13(2):97\u2013105.","journal-title":"J Psychiatr Pract"},{"issue":"12","key":"2687_CR20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa052964","volume":"354","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243\u201352. https:\/\/doi.org\/10.1056\/NEJMoa052964.","journal-title":"N Engl J Med"},{"key":"2687_CR21","volume-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","author":"Association AP","year":"2002","unstructured":"Association AP. Practice guideline for the treatment of patients with bipolar disorder (revision). American Psychiatric Pub; 2002."},{"issue":"1","key":"2687_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/ajp.157.1.1","volume":"157","author":"Association AP","year":"2000","unstructured":"Association AP. Practice guideline for the treatment of patients with eating disorders (revision). Am J Psychiatry. 2000;157(1):1.","journal-title":"Am J Psychiatry"},{"key":"2687_CR23","first-page":"S393","volume":"15","author":"J Wijkstra","year":"2005","unstructured":"Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for psychotic depression: Cochrane systematic review and meta-analysis. Eur Neuropsychopharmacol. 2005;15:S393.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"2687_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11096-018-0724-7","volume":"41","author":"A Chastang","year":"2019","unstructured":"Chastang A, Renet S, Corny J, Beaussier H, Petre A, Lillo-Lelouet A, et al. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. Int J Clin Pharm. 2019;41(1):42\u20138. https:\/\/doi.org\/10.1007\/s11096-018-0724-7.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"2687_CR25","doi-asserted-by":"publisher","first-page":"e016627","DOI":"10.1136\/bmjopen-2017-016627","volume":"7","author":"AL Coughtrie","year":"2017","unstructured":"Coughtrie AL, Behr ER, Layton D, Marshall V, Camm AJ, Shakir SAW. Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open. 2017;7(10):e016627. https:\/\/doi.org\/10.1136\/bmjopen-2017-016627.","journal-title":"BMJ Open"},{"issue":"3","key":"2687_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/B:PHAR.0000026800.13888.b0","volume":"26","author":"R Viola","year":"2004","unstructured":"Viola R, Csukonyi K, Doro P, Janka Z, Soos G. Reasons for polypharmacy among psychiatric patients. Pharm World Sci. 2004;26(3):143\u20137. https:\/\/doi.org\/10.1023\/B:PHAR.0000026800.13888.b0.","journal-title":"Pharm World Sci"},{"issue":"1","key":"2687_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/13651501.2016.1234623","volume":"21","author":"CM Rodriguez-Leal","year":"2017","unstructured":"Rodriguez-Leal CM, Lopez-Lunar E, Carrascosa-Bernaldez JM, Provencio-Arranz RM. Electrocardiographic surveillance in a psychiatric institution: avoiding iatrogenic cardiovascular death. Int J Psychiatry Clin Pract. 2017;21(1):64\u20136. https:\/\/doi.org\/10.1080\/13651501.2016.1234623.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"1","key":"2687_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1039856217726212","volume":"26","author":"I Berling","year":"2018","unstructured":"Berling I, Gupta R, Bjorksten C, Prior F, Whyte IM, Berry S. A review of ECG and QT interval measurement use in a public psychiatric inpatient setting. Australas Psychiatry. 2018;26(1):50\u20135. https:\/\/doi.org\/10.1177\/1039856217726212.","journal-title":"Australas Psychiatry"},{"issue":"1","key":"2687_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","volume":"54","author":"SR Beach","year":"2013","unstructured":"Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1\u201313. https:\/\/doi.org\/10.1016\/j.psym.2012.11.001.","journal-title":"Psychosomatics."},{"issue":"1","key":"2687_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","volume":"53","author":"LS Fridericia","year":"1920","unstructured":"Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica. 1920;53(1):469\u201386.","journal-title":"Acta Medica Scandinavica"},{"key":"2687_CR31","first-page":"353","volume":"7","author":"HC Bazett","year":"1920","unstructured":"Bazett HC. An analysis of the time relations of electrocardiograms. Heart. 1920;7:353\u201370.","journal-title":"Heart."},{"issue":"3","key":"2687_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","volume":"17","author":"I Goldenberg","year":"2006","unstructured":"Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is \"normal\". J Cardiovasc Electrophysiol. 2006;17(3):333\u20136. https:\/\/doi.org\/10.1111\/j.1540-8167.2006.00408.x.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"10","key":"2687_CR33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013\u201322. https:\/\/doi.org\/10.1056\/NEJMra032426.","journal-title":"N Engl J Med"},{"key":"2687_CR34","volume-title":"Micromedex Drug-Reax\u00ae","author":"Micromedex-DrugReax\u00ae","year":"2018","unstructured":"Micromedex-DrugReax\u00ae. Micromedex Drug-Reax\u00ae. Greenwood Village: Truven Health Analytics; 2018. https:\/\/www.micromedexsolutions.com\/home\/dispatch\/ssl\/true. Accessed 8 Sept 2018."},{"issue":"4","key":"2687_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0447.1996.tb10653.x","volume":"93","author":"JP Warner","year":"1996","unstructured":"Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 1996;93(4):311\u20133. https:\/\/doi.org\/10.1111\/j.1600-0447.1996.tb10653.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"2687_CR36","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.4088\/JCP.v66n1107","volume":"66","author":"P Mackin","year":"2005","unstructured":"Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry. 2005;66(11):1386\u201391.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2687_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cbm.630","volume":"17","author":"S Girgis","year":"2007","unstructured":"Girgis S, Huckstep B, Oakley J, Ferriter M, Nikolaou V. QTc-interval abnormalities in a forensic population. Crim Behav Ment Health. 2007;17(2):75\u201388. https:\/\/doi.org\/10.1002\/cbm.630.","journal-title":"Crim Behav Ment Health"},{"key":"2687_CR38","first-page":"149","volume":"11","author":"Y Ozeki","year":"2008","unstructured":"Ozeki Y, Aoki T, Fujii K, Kurimoto N, Takahashi J, Ishida N, et al. Risk factors of QT interval prolongation in Japanese patients with schizophrenia. Int J Neuropsychopharmacol. 2008;11:149.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"2687_CR39","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1176\/appi.ajp.2013.12060860","volume":"170","author":"FR Girardin","year":"2013","unstructured":"Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG screening outcome in psychiatry study. Am J Psychiatry. 2013;170(12):1468\u201376. https:\/\/doi.org\/10.1176\/appi.ajp.2013.12060860.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2687_CR40","doi-asserted-by":"publisher","first-page":"e0127213","DOI":"10.1371\/journal.pone.0127213","volume":"10","author":"A Poncet","year":"2015","unstructured":"Poncet A, Gencer B, Blondon M, Gex-Fabry M, Combescure C, Shah D, et al. Electrocardiographic screening for prolonged QT interval to reduce sudden cardiac death in psychiatric patients: a cost-effectiveness analysis. PLoS One. 2015;10(6):e0127213. https:\/\/doi.org\/10.1371\/journal.pone.0127213.","journal-title":"PLoS One"},{"issue":"2","key":"2687_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajem.2014.09.048","volume":"33","author":"N Miura","year":"2015","unstructured":"Miura N, Saito T, Taira T, Umebachi R, Inokuchi S. Risk factors for QT prolongation associated with acute psychotropic drug overdose. Am J Emerg Med. 2015;33(2):142\u20139. https:\/\/doi.org\/10.1016\/j.ajem.2014.09.048.","journal-title":"Am J Emerg Med"},{"issue":"4","key":"2687_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jelectrocard.2004.07.001","volume":"37","author":"T Sadanaga","year":"2004","unstructured":"Sadanaga T, Sadanaga F, Yao H, Fujishima M. Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation. J Electrocardiol. 2004;37(4):267\u201373. https:\/\/doi.org\/10.1016\/j.jelectrocard.2004.07.001.","journal-title":"J Electrocardiol"},{"issue":"1","key":"2687_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.schres.2009.09.041","volume":"116","author":"R Ramos-Rios","year":"2010","unstructured":"Ramos-Rios R, Arrojo-Romero M, Paz-Silva E, Carballal-Calvo F, Bouzon-Barreiro JL, Seoane-Prado J, et al. QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res. 2010;116(1):35\u201343. https:\/\/doi.org\/10.1016\/j.schres.2009.09.041.","journal-title":"Schizophr Res"},{"issue":"1","key":"2687_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00213-011-2188-5","volume":"216","author":"FD Yang","year":"2011","unstructured":"Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, et al. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology. 2011;216(1):9\u201316. https:\/\/doi.org\/10.1007\/s00213-011-2188-5.","journal-title":"Psychopharmacology."},{"issue":"5","key":"2687_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/070674371506000502","volume":"60","author":"SW Rabkin","year":"2015","unstructured":"Rabkin SW. Impact of age and sex on QT prolongation in patients receiving Psychotropics. Can J Psychiatr. 2015;60(5):206\u201314. https:\/\/doi.org\/10.1177\/070674371506000502.","journal-title":"Can J Psychiatr"},{"issue":"9209","key":"2687_CR46","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","volume":"355","author":"JG Reilly","year":"2000","unstructured":"Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(00)02035-3.","journal-title":"Lancet."},{"issue":"2","key":"2687_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","volume":"34","author":"Y Ozeki","year":"2010","unstructured":"Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(2):401\u20135. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.01.008.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"2687_CR48","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424\u201332. https:\/\/doi.org\/10.1007\/s11096-017-0446-2.","journal-title":"Int J Clin Pharm"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02687-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02687-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02687-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T02:55:02Z","timestamp":1622688902000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02687-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2687"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02687-w","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"5 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Institutional Review Board (IRB) of Medical Teaching Institute (MTI), Lady Reading Hospital (LRH), Peshawar, Khyber Pakhtunkhwa, Pakistan vide reference number 09\/1RB. Before participation written consent was taken from each participant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}